المؤلفون: Mack, SC, Witt, H, Piro, RM, Gu, L, Zuyderduyn, S, Stütz, AM, Wang, X, Gallo, M, Garzia, L, Zayne, K, Zhang, X, Ramaswamy, V, Jäger, N, Jones, DTW, Sill, M, Pugh, TJ, Ryzhova, M, Wani, KM, Shih, DJH, Head, R, Remke, M, Bailey, SD, Zichner, T, Faria, CC, Barszczyk, M, Stark, S, Seker-Cin, H, Hutter, S, Johann, P, Bender, S, Hovestadt, V, Tzaridis, T, Dubuc, AM, Northcott, PA, Peacock, J, Bertrand, KC, Agnihotri, S, Cavalli, FMG, Clarke, I, Nethery-Brokx, K, Creasy, CL, Verma, SK, Koster, J, Wu, X, Yao, Y, Milde, T, Sin-Chan, P, Zuccaro, J, Lau, L, Pereira, S, Castelo-Branco, P, Hirst, M, Marra, MA, Roberts, SS, Fults, D, Massimi, L, Cho, YJ, Van Meter, T, Grajkowska, W, Lach, B, Kulozik, AE, von Deimling, A, Witt, O, Scherer, SW, Fan, X, Muraszko, KM, Kool, M, Pomeroy, SL, Gupta, N, Phillips, J, Huang, A, Tabori, U, Hawkins, C, Malkin, D, Kongkham, PN, Weiss, WA, Jabado, N, Rutka, JT, Bouffet, E, Korbel, JO, Lupien, M, Aldape, KD, Bader, GD, Eils, R, Lichter, P, Dirks, PB, Pfister, SM, Korshunov, A, Taylor, MD

المصدر: Nature. 506(7489)

مصطلحات موضوعية: Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Pediatric, Human Genome, Rare Diseases, Animals, Brain Neoplasms, CpG Islands, DNA Methylation, Embryonic Stem Cells, Ependymoma, Epigenesis, Genetic, Epigenomics, Female, Gene Expression Regulation, Neoplastic, Gene Silencing, Histones, Humans, Infant, Mice, Mice, Inbred NOD, Mice, SCID, Mutation, Phenotype, Polycomb Repressive Complex 2, Prognosis, Rhombencephalon, Xenograft Model Antitumor Assays, General Science & Technology

وصف الملف: application/pdf

URL الوصول: https://escholarship.org/uc/item/60w365s8

المؤلفون: Nakazawa MS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Silverman IM; Repare Therapeutics, Cambridge, Massachusetts., Rimkunas V; Repare Therapeutics, Cambridge, Massachusetts., Veloso A; Repare Therapeutics, Cambridge, Massachusetts., Glodzik D; Repare Therapeutics, Cambridge, Massachusetts., Johnson A; Repare Therapeutics, Cambridge, Massachusetts., Ohsumi TK; Repare Therapeutics, Cambridge, Massachusetts., Patel SR; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Soliman PT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Beird HC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wu CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ingram DR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Song D; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lazar AJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Livingston JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Jul 02; Vol. 23 (7), pp. 1057-1065.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Ribonuclease H*/genetics , Leiomyosarcoma*/genetics , Leiomyosarcoma*/pathology , Leiomyosarcoma*/mortality , DNA Repair*, Humans ; Female ; Biomarkers, Tumor/genetics ; Male ; Prognosis ; Middle Aged ; Aged ; DNA Damage

المؤلفون: Bowen MB; The University of Texas MD Anderson Cancer Center, United States., Melendez B; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zhang Q; M. D. Anderson Cancer Center, Houston, United States., Yang RK; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Fellman BM; The University of Texas MD Anderson Cancer Center, Houston, United States., Lawson BC; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Adjei NN; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Celestino J; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wani KM; The University of Texas MD Anderson Cancer Center, Houston, Tx, United States., Singh B; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Urbauer DL; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lazar AJ; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lu KH; The University of Texas MD Anderson Cancer Center, Houston, Tx, United States., Wargo JA; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Westin SN; U.T. M.D. Anderson Cancer Center, Houston, TX, United States., Yates MS; University of North Carolina School of Medicine, Chapel Hill, NC, United States.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Jun 26. Date of Electronic Publication: 2024 Jun 26.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

المؤلفون: Pilié PG; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Giuliani V; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio., Bristow CA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ngoi NYL; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kyewalabye K; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Le H; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Campbell E; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sanchez NS; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Yang D; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gheeya JS; The University of Texas Health Science Center at Houston, Houston, Texas., Goswamy RV; The University of Texas Health Science Center at Houston, Houston, Texas., Holla V; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shaw KR; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Meric-Bernstam F; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Liu CY; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Ma X; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng N; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Machado AA; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Bardenhagen JP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Vellano CP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Marszalek JR; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Rajendra E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Piscitello D; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Johnson TI; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Likhatcheva M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Elinati E; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Majithiya J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Neves J; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Grinkevich V; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Ranzani M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Luzarraga MR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Boursier M; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Armstrong L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Geo L; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lillo G; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Tse WY; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kopetz SE; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Geck Do MK; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lively S; ChemPartner Corporation, San Francisco, California., Johnson MG; ChemPartner Corporation, San Francisco, California., Robinson HMR; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Smith GCM; Artios Pharma, the Glenn Berge Building, Babraham Research Campus, Cambridge, United Kingdom., Carroll CL; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Di Francesco ME; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Jones P; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas., Heffernan TP; TRACTION (Translational Research to Advance Therapeutics and Innovation in Oncology), The University of Texas MD Anderson Cancer Center, Houston, Texas., Yap TA; Department of Investigational Cancer Therapeutics (Phase I Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2121-2139.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Ataxia Telangiectasia Mutated Proteins*/genetics , Ataxia Telangiectasia Mutated Proteins*/antagonists & inhibitors , Neoplasms*/genetics , Neoplasms*/drug therapy , Neoplasms*/pathology, Animals ; Humans ; Mice ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/genetics ; Cell Line, Tumor ; Loss of Function Mutation ; Xenograft Model Antitumor Assays

المؤلفون: Hahn AW; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Menk AV; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania., Rivadeneira DB; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania., Augustin RC; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., Xu M; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Li J; Department of Bioinformatics and Computational Biology, Division of Basic Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas., Wu X; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Mishra AK; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Gide TN; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Quek C; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Zang Y; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, California., Menzies AM; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Daniel CR; Department of Epidemiology, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas., Hudgens CW; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Nowicki T; Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California., Haydu LE; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Khan MAW; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Gopalakrishnan V; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Burton EM; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Malke J; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Simon JM; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Bernatchez C; Department of Biologics Development, Division of Therapeutics Discovery, University of Texas MD Anderson Cancer Center, Houston, Texas., Putluri N; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Woodman SE; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Vashisht Gopal YN; Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Guerrieri R; Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Fischer GM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Wang J; Department of Biostatistics, Division of Biosciences, University of Texas MD Anderson Cancer Center, Houston, Texas., Wani KM; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Thompson JF; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Lee JE; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Hwu P; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa Bay, Florida., Ajami N; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Gershenwald JE; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California., Long GV; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia., Scolyer RA; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia., Tetzlaff MT; Division of Dermatopathology, Department of Pathology, University of California San Francisco, San Francisco, California., Lazar AJ; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Schadendorf D; Department of Dermatology, Venereology, and Allergology, University Hospital Essen and German Cancer Consortium, Partner site Essen, Germany., Wargo JA; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Surgical Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Kirkwood JM; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., DeBerardinis RJ; Children's Medical Research Institute and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas., Liang H; Department of Bioinformatics and Computational Biology, Division of Basic Sciences, University of Texas MD Anderson Cancer Center, Houston, Texas., Futreal A; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Zhang J; Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Wilmott JS; Melanoma Institute of Australia, The University of Sydney, Sydney, New South Wales, Australia., Peng W; Department of Biology and Biochemistry, University of Houston, Houston, Texas., Davies MA; Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas., Delgoffe GM; Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania., Najjar YG; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., McQuade JL; Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jan 04; Vol. 29 (1), pp. 154-164.

نوع المنشور: Editorial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Comment

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/genetics , Melanoma*/complications , Neoplasms, Second Primary*, Humans ; Risk Factors ; DNA Copy Number Variations ; Obesity/complications ; Overweight ; Body Mass Index

المؤلفون: Lazcano R; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Barreto CM; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Salazar R; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Carapeto F; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Traweek RS; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Leung CH; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Gite S; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Mehta J; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ingram DR; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wani KM; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Vu KT; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Parra ER; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lu W; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zhou J; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Witt RG; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Cope B; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Thirasastr P; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Lin HY; Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Scally CP; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Conley AP; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ratan R; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Livingston JA; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Zarzour AM; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ludwig J; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Araujo D; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ravi V; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Patel S; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Benjamin R; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wargo J; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wistuba II; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States., Somaiah N; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Roland CL; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Keung EZ; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Solis L; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Wang WL; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States., Lazar AJ; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.; Division of Pathology and Laboratory Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.; Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Nassif EF; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

المصدر: Frontiers in oncology [Front Oncol] 2022 Oct 12; Vol. 12, pp. 1008484. Date of Electronic Publication: 2022 Oct 12 (Print Publication: 2022).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

المؤلفون: Andrews MC; Department of Medicine, Monash University, Melbourne, VIC, Australia.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Oba J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan., Wu CJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhu H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karpinets T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Creasy CA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yu X; Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mao X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Robertson AG; Canada's Michael Smith Genome Sciences Center, BC Cancer, Vancouver, BC, Canada.; Dxige Research Inc., Courtenay, BC, Canada., Romano G; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sloane RS; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wani KM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rai K; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar AJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haydu LE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bustos MA; Departments of Translational Molecular Medicine and Genomic Sequencing Center, St John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA., Shen J; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA., Chen Y; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Smithville, TX, USA., Morgan MB; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kwong LN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grimm EA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; H Lee Moffitt Cancer Center, Tampa, FL, USA., Hoon DSB; Departments of Translational Molecular Medicine and Genomic Sequencing Center, St John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Biologics Development, Division of Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Woodman SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swoodman@mdanderson.org.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swoodman@mdanderson.org.

المصدر: Nature communications [Nat Commun] 2022 Jul 09; Vol. 13 (1), pp. 4000. Date of Electronic Publication: 2022 Jul 09.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: Melanoma*/metabolism , Melanoma*/pathology , MicroRNAs*/metabolism , RNA, Long Noncoding*/metabolism, DNA Methylation ; Humans ; Transcriptome

المؤلفون: Gaur SS; Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India., Dhar P; Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India., Wani KM; Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India., Srivastava M; Department of Chemical Engineering, National Institute of Technology Agartala, Tripura 799046, India., Sakurai S; Department of Bio-based Materials Science, Kyoto Institute of Technology, Kyoto 606-8585, Japan., Kumar A; Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India., Katiyar V; Department of Chemical Engineering, Indian Institute of Technology Guwahati, Guwahati, Assam 781039, India. Electronic address: vkatiyar@iitg.ac.in.

المصدر: Journal of colloid and interface science [J Colloid Interface Sci] 2021 Apr; Vol. 587, pp. 214-228. Date of Electronic Publication: 2020 Dec 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Academic Press Country of Publication: United States NLM ID: 0043125 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-7103 (Electronic) Linking ISSN: 00219797 NLM ISO Abbreviation: J Colloid Interface Sci Subsets: MEDLINE

مواضيع طبية MeSH: Polyvinyl Alcohol* , Water*, Anions ; Electric Conductivity ; Humans ; Methanol

المؤلفون: Qin Y; Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, El Paso, Texas, USA., Bollin K; Medical Oncology, Scripps MD Anderson Cancer Center, San Diego, California, USA., de Macedo MP; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Carapeto F; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Kim KB; Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, California, USA., Roszik J; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wani KM; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reuben A; Thoracic/Head & Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reddy ST; Neurology, University of Texas Health Science Center at Houston, Houston, Texas, USA., Williams MD; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Tetzlaff MT; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang WL; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gombos DS; Department of Head and Neck Surgery, Section of Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Esmaeli B; Orbital Oncology & Ophthalmic Plastic Surgery, Department of Plastic Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lazar AJ; Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwu P; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Patel SP; Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA sppatel@mdanderson.org.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Nov; Vol. 8 (2).

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Biomarkers, Tumor/*metabolism , Immunotherapy/*methods , Melanoma/*drug therapy , Melanoma/*immunology , Uveal Neoplasms/*drug therapy , Uveal Neoplasms/*immunology, Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged

SCR Disease Name: Uveal melanoma

المؤلفون: Petitprez F; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France.; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France., de Reyniès A; Programme Cartes d'Identité des Tumeurs, Ligue Nationale Contre le Cancer, Paris, France., Keung EZ; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chen TW; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; National Taiwan University Cancer Center, Taipei, Taiwan.; Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan., Sun CM; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Calderaro J; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Département de Pathologie, Assistance Publique Hôpitaux de Paris, Groupe Hospitalier Henri Mondor, Creteil, France.; Institut Mondor de Recherche Biomédicale, Creteil, France., Jeng YM; Centers of Genomic and Precision Medicine, National Taiwan University, Taipei, Taiwan.; Department of Pathology, National Taiwan University, Taipei, Taiwan., Hsiao LP; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Lacroix L; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Bougoüin A; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Moreira M; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Lacroix G; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Natario I; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Adam J; Department of Biology and Pathology, Gustave Roussy, Villejuif, France., Lucchesi C; Institut Bergonié, Bordeaux, France.; Bioinformatics Unit, Institut Bergonié, Bordeaux, France., Laizet YH; Institut Bergonié, Bordeaux, France.; Bioinformatics Unit, Institut Bergonié, Bordeaux, France., Toulmonde M; Institut Bergonié, Bordeaux, France.; Department of Medical Oncology, Institut Bergonié, Bordeaux, France., Burgess MA; Department of Medicine, Divison of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA., Bolejack V; Cancer Research and Biostatistics, Seattle, WA, USA., Reinke D; Sarcoma Alliance for Research Through Collaboration, Ann Arbor, MI, USA., Wani KM; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Roland CL; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Italiano A; Institut Bergonié, Bordeaux, France.; Department of Medical Oncology, Institut Bergonié, Bordeaux, France.; University of Bordeaux, Bordeaux, France., Sautès-Fridman C; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France., Tawbi HA; Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. htawbi@mdanderson.org., Fridman WH; Team Cancer, Immune Control and Escape, Centre de Recherche des Cordeliers, INSERM, Paris, France. herve.fridman@crc.jussieu.fr.; Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Paris Cite, Paris, France. herve.fridman@crc.jussieu.fr.; Centre de Recherche des Cordeliers, Sorbonne University, Paris, France. herve.fridman@crc.jussieu.fr.

المصدر: Nature [Nature] 2020 Jan; Vol. 577 (7791), pp. 556-560. Date of Electronic Publication: 2020 Jan 15.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE

مواضيع طبية MeSH: Immunotherapy*, B-Lymphocytes/*immunology , Sarcoma/*drug therapy , Sarcoma/*immunology , Tertiary Lymphoid Structures/*immunology, Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; CD8-Positive T-Lymphocytes/immunology ; Cohort Studies ; Dendritic Cells, Follicular/immunology ; Humans ; Mutation ; Phenotype ; Prognosis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Reproducibility of Results ; Sarcoma/classification ; Sarcoma/pathology ; Survival Rate ; Tumor Microenvironment